The responses of 47 patients with non-dystrophic myotonia to a French questionnaire on the impact of myotonia (French IMPACT survey 2022) showed that :
- the main symptoms reported were muscular stiffness (98%), muscular pain (83%), falls (70%) and anxiety (77%), which had a severe impact on their daily lives;
- a large majority of patients (96%) were taking a pharmacological treatment (91% of them mexiletine) to reduce these symptoms, with a high satisfaction rate (91.5%);
- a third of participants gave a positive assessment of their quality of life.
